Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597809 | 0.76 | IDO1 (0.36) | IDO1 | |
| SCHEMBL16538251 | 0.74 | ALDH1A1 (0.38) | ALDH1A1GAAIDO1 | |
| SCHEMBL20289108 | 0.72 | ALDH1A3 (0.30) | — | |
| SCHEMBL15557732 | 0.69 | ALDH1A1 (0.35) | ALDH1A1GAAIDO1 | |
| SCHEMBL16388499 | 0.69 | HRH4 (0.35) | ALDH1A1GAAIDO1 | |
| SCHEMBL21993838 | 0.68 | CD44 (0.39) | ALDH1A1GAA | |
| SCHEMBL30216060 | 0.67 | KDM1A (0.38) | GAA | |
| SCHEMBL1494553 | 0.67 | KDM1A (0.38) | GAA | |
| SCHEMBL2374749 | 0.66 | S100B (0.35) | ALDH1A1GAA | |
| SCHEMBL31520822 | 0.64 | LMNA (0.40) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| EP-3039020-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3039020-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3039020-A1 | IDO INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031295-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031295-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | ALDH1A1 996/4885GAA 369/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.